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Clozapine withdrawal psychosis is a relatively well-recognized phenomenon. However, literature ex-
ploring clozapine withdrawal associated catatonia is limited to a few case reports [Bastiampillai, 2009]. 
We present a case of clozapine withdrawal catatonia, psychosis and associated neuroleptic malignant 
syndrome (NMS) and discuss its clinical implications. 
Mr. C is a 44 year old man, who was well managed on clozapine 200 mg nocte and paliperidone depot 
75 mg 4 weekly for schizoaffective disorder with no past history of catatonia. He presented with recent 
onset atypical chest pain with a raised troponin of 81 ng/L.  Clozapine was discontinued abruptly due 
to suspected myocarditis. Cardiology evaluation definitively excluded myocarditis following normal 
cardiac investigations. He had received his depot paliperidone two weeks preceding clozapine cessa-
tion.  
On day seven, following clozapine cessation, he developed autonomic instability and worsening clini-
cal features of mutism, gegenhalten rigidity, perseveration, catalepsy, staring, bizarre mannerisms, 
stereotypy with head rocking from side to side and diaphoresis. His CK was elevated to 1740 u/L and 
he was afebrile. This phenomenon of clozapine withdrawal catatonia was initially unrecognised and 
interpreted instead as solely clozapine withdrawal NMS. Retrospective Bush Francis Catatonia Rating 
Scale (BFCRS) scored 41 on day nine.  Given the diagnosis of NMS, neuroleptics were avoided and Mr. 
C was managed on Lorazepam 9 mg/day. On retrospective chart review, his catatonic symptoms re-
sponded within 72 hours with resolution of mutism, rigidity and autonomic instability with BFCRS re-
ducing to 4.  
 
 
On day ten, however, clozapine rebound psychosis manifested with auditory hallucinations, labile af-
fect and intrusive behaviour. With suspected diagnosis of NMS, use of any antipsychotics including 
clozapine was avoided. On day twelve, olanzapine 5 mg was given. However, within 48 hours, he rap-
idly deteriorated with return of rigidity, bradykinesia, tachycardia and diaphoresis without fever. The 
severity was such that he was unable to blink to visual confrontation and his CK rose significantly to 
6858 u/L. Mr. C was diagnosed to have olanzapine induced NMS and was managed in an ICU setting 
with benzodiazepines but with minimal response. 
Following consultation with the psychiatry team, he was now diagnosed as having clozapine with-
drawal psychosis and with caution clozapine was initiated and gradually up-titrated 12.5 mg every 2 
days without inducing NMS. Clozapine was gradually increased to 200 mg dose within 4 weeks with 
complete clinical response and no further complications.  
Abrupt cessation of clozapine results in withdrawal symptoms affecting various receptor sites and 
neurotransmitters [Stahl, 2013]. Case reports of clozapine withdrawal catatonia have been rarely de-
scribed with onset ranging from immediate to 7 days. It is hypothesised that clozapine has GABA ago-
nist properties and sudden clozapine withdrawal may result in sudden decrease in GABA activity that 
may contribute to the development of catatonic symptoms in predisposed patients[Bilbily et al, 2017]. 
In our case, it is noteworthy that olanzapine likely induced severe NMS following period of clozapine 
withdrawal catatonia.  It is also likely that paliperidone may have contributed to the NMS component 
that accompanied the initial episode of clozapine withdrawal catatonia [Northoff, 2002]. It probably 
indicates that caution should be exercised with the use of other neuroleptics in a patient undergoing 
sudden clozapine withdrawal  [Kurien et al., 2013].  
Clozapine withdrawal psychosis is well recognised and has been documented with onset within 14 
days. The mechanism likely relates to loose binding to DA2 receptors, compensatory increases in DA2 
following chronic administration, its therapeutic effectiveness with much lower DA2 occupancy (Mil-
ler, 2009) and potentially rebound effects from other receptors: mainly cholinergic but to a lesser 
extent serotonergic, noradrenergic and GABA-ergic receptors (Shields et al., 2012). The main thera-
peutic strategy to resolve clozapine withdrawal psychosis is reinstatement of clozapine, which was 
delayed in this case due to concerns about induction of NMS. 
Our case highlights the importance of understanding the potentially complex symptom profile follow-
ing sudden clozapine withdrawal, which can often trigger withdrawal psychosis and rarely also with-
drawal catatonia. It is very important to clinically recognise this withdrawal state and reinstate clozap-
ine as quickly as possible, understanding that benzodiazepines could specifically address the with-
 
 
drawal catatonia as an adjunctive agent [Daniels, 2009]. Administering other antipsychotics in the set-
ting of clozapine withdrawal will likely not address either clozapine withdrawal psychosis or catatonia 
and could instead cause clinical deterioration by worsening catatonia or inducing NMS in predisposed 
patients. [Lee et al., 1997] 
A better understanding of clozapine withdrawal catatonia and psychosis may also allow us to better 
analyse the unique properties of clozapine, with possible suggestion that it could be a GABA agent 
further supporting the importance of the GABA system in schizophrenia. [O’Connor and O‘Shea, 2015]
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